- Home
- ONCY vs AVTX Comparison
ONCY vs AVTX Comparison
Compare ONCY & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ONCY
- AVTX
- Stock Information
- Founded
- ONCY 1998
- AVTX 2011
- Country
- ONCY Canada
- AVTX United States
- Employees
- ONCY N/A
- AVTX N/A
- Industry
- ONCY Pharmaceuticals and Biotechnology
- AVTX Biotechnology: Pharmaceutical Preparations
- Sector
- ONCY Health Care
- AVTX Health Care
- Exchange
- ONCY Nasdaq
- AVTX Nasdaq
- Market Cap
- ONCY 86.1M
- AVTX 90.9M
- IPO Year
- ONCY 1999
- AVTX 2015
- Fundamental
- Price
- ONCY $0.76
- AVTX $9.41
- Analyst Decision
- ONCY Strong Buy
- AVTX Buy
- Analyst Count
- ONCY 2
- AVTX 3
- Target Price
- ONCY $4.00
- AVTX $29.50
- AVG Volume (30 Days)
- ONCY 359.4K
- AVTX 90.5K
- Earning Date
- ONCY 11-12-2024
- AVTX 11-07-2024
- Dividend Yield
- ONCY N/A
- AVTX N/A
- EPS Growth
- ONCY N/A
- AVTX N/A
- EPS
- ONCY N/A
- AVTX N/A
- Revenue
- ONCY N/A
- AVTX $820,000.00
- Revenue This Year
- ONCY N/A
- AVTX N/A
- Revenue Next Year
- ONCY N/A
- AVTX N/A
- P/E Ratio
- ONCY N/A
- AVTX N/A
- Revenue Growth
- ONCY N/A
- AVTX N/A
- 52 Week Low
- ONCY $0.76
- AVTX $3.95
- 52 Week High
- ONCY $1.53
- AVTX $34.46
- Technical
- Relative Strength Index (RSI)
- ONCY 26.96
- AVTX 42.72
- Support Level
- ONCY $0.91
- AVTX $9.00
- Resistance Level
- ONCY $0.88
- AVTX $9.82
- Average True Range (ATR)
- ONCY 0.04
- AVTX 0.75
- MACD
- ONCY -0.01
- AVTX 0.01
- Stochastic Oscillator
- ONCY 11.12
- AVTX 27.86
About ONCY Oncolytics Biotech Inc.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatment. The other projects in the company's pipeline include, Bracelet-1 for treatment of Breast Cancer, Goblet cohort-1, Goblet cohort-5 for treatment of Gastro-Intestinal Cancer among others.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical stage biotechnology company focused on the treatment of immune dysregulation. The company's lead asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).